BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Blogs » BioWorld MedTech Perspectives » Be honest, be open, and be upfront about devices

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Be honest, be open, and be upfront about devices

May 6, 2011
By Omar Ford
No Comments

A couple of weeks ago I interviewed PixelOptics' president/CEO Ron Blum, about a technology called emPower, a device that could eventually replace bifocals.

Now there's one thing you need to know about the interview. 

 Blum is one of those people that med-tech journalists just love to talk to. He’s honest, upfront and has a sort of passion about his product that you just don’t see that often. He’s not  regurgitating facts, or bedazzling you with technical terms that can sometimes go straight over your head.

But rather, Blum is a master of his craft. And if  emPower is anything like its CEO, then we’re going to have a lot less people wearing bifocals in the near future - because he is just that convincing.   

And here’s what I think some med-tech companies are missing. They’re missing that one person who is tailor made to get their point across. Companies are missing that person who has the power and the authority to have an honest conversation about the technology and kick out a lot of P.R. jargon that tends to creep up in interviews.

My only problem with the Blum interview is that it couldn’t go longer. But alas deadlines are a harsh reality for daily publications.

My point is this, when companies are trying to get out the message about their products, they should talk a little bit about what the product could mean for the patient. Don’t give numbers or stats, those will most likely be presented in the press release. Instead try to personalize the experience, let the interviewer and the audience know what’s at stake.

Blum, with so much media attention placed on emPower was fully aware of the stakes and was brutally honest with Medical Device Daily about what that meant for him and the company.

He told me, “When you have this kind of attention on a [global scale], which is at least in our industry unprecedented, it's tremendous pressure on a company like PixelOptics to make sure its product lives up to the promise that we deliver what it is we say we're going to deliver."

If only more companies could open up like this.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing